HEALTH PROMOTION FOR GAY, BISEXUAL, QUEER AND OTHER MEN WHO HAVE SEX WITH MEN (MSM) AND TRANSGENDER WOMEN (TW)

HPV and ANAL CANCER SCREENING TREATMENT and CARE

REVIEWED BY JORDAN GOODRIDGE, BHSc, MD, CCFP SEPTEMBER 9, 2024



ABOUT THIS FACTSHEET

This fact sheet is for front-line, outreach staff, public health staff, others providing sexual health care and the communities of men who have sex with men (MSM) and transgender women (TW). In the 2024 International Anal Neoplasia guidelines, MSM and TW living with HIV are prioritized for anal cancer screening.

WHAT IS HPV?

Human papillomavirus (HPV) is a group of over 200 viruses that can cause cancer and skin warts, including anal warts. HPV strains (types) are divided into high-risk types, which can lead to cancer, and lowrisk types, which usually cause warts.¹

Nearly 50% of HPV infections are due to a high-risk strains, with around 14 identified high-risk strains. These HPV strains can cause cancer in the anus (the outermost part of the bum), mouth, throat and penis, as well as the cervix, vagina and vulva in AFAB—assigned female at birth individuals.¹⁻⁵

Most of the time, the immune system controls HPV infections to stop them from causing cancer.¹ Due to a higher likelihood of having weakened immune systems, people living with HIV (PLHIV) are more likely to get anal cancer from the virus.^{1,3,6-11}

HOW DO YOU GET HPV?

HPV can be spread non-sexually or sexually through vaginal, front hole, anal, or oral sex.^{1,12}

Nearly all sexually active people will become infected with HPV at some point after becoming sexually active.^{1,13} Sharing materials such as towels or other items with people living with low-risk HPV types can also transmit the virus.²

HOW DOES HPV CAUSE ANAL CANCER?

HPV can cause abnormal cell changes, or 'dysplasia,' over several years, especially when high-risk strains are not cleared by the immune system. If left untreated, progression may occur to precancer and then cancer, especially if HPV infection persists for years rather than being cleared by the body.^{1-3,6-8,14} This may happen in many parts of the body, including the anus.^{1,3}

The MSM and trans women communities, and particularly older PLHIV in these groups, are much more at risk than the general population to get anal cancer from HPV infection.^{1,3,4,6-8,11,15} Other factors to consider include—but are not limited to—cigarette smoking, having anal warts, having multiple sexual partners, anal-receptive intercourse (bottoming) and immunosuppression (e.g., organ transplantation).^{1-3,9,11}

SYMPTOMS OF HPV, WARTS AND ANAL CANCER

Some people can have HPV in their bodies for weeks to a lifetime without symptoms. However, in others, the strain of HPV will result in either warts or cancer.¹³

For high-risk HPV types, people may not notice anything for years until cancer growth causes lumps, itchiness, discharge, bleeding, pain or pressure in or around the anus and/or a change in bowel habits.^{1,16}

For low-risk HPV types, warts on or around the genitals, anus, mouth or throat are possible.¹ These warts may be light brown, yellow, pink, or fleshcoloured, raised or flat, and broad, looking somewhat like cauliflower.^{2,13} The number of warts can vary from one to a large group.² They usually do not cause other symptoms, but bleeding, itchiness and pain can occur.^{2,13}

SCREENING FOR HPV AND ANAL CANCER

Digital anal rectal examination (DARE), anal pap smear and high resolution anoscopy (HRA) are some methods to screen for anal cancer. The method(s) chosen vary mostly by local availability and cost.^{3,15,17}

DARE allows for a healthcare provider (HCP) to check for any warts, lumps, swelling, masses or other irregularities in the bum using a gloved finger. DARE is most useful for detecting some cancer cases early on.³ It does not check for possible changes in cells made by HPV. For PLHIV and for people who engage in receptive anal sex (bottoming), one DARE is recommended every year.¹⁰

Anal papanicolaou (pap) smears are performed by putting a small swab into the anus and lower part of the rectum to collect cells that can later be looked at under a microscope. Cells may show changes from "normal"-appearing cells to precancerous and cancerous ones, guiding HCP treatment decisions.^{3,10,18}

In HRA, a thin, flexible tube with a light and magnifying device is put in the anus to let the HCP have a view of the anal and rectal areas (deeper inside).^{10,19} In people who have more developed precancerous cell changes, cells can also be taken in a biopsy to examine for any HPV-related cell changes. Despite its uses, HRA is not widely available across Canada, making it not a feasible option for most people's care.¹⁰ PLHIV may benefit from the combination of DARE, an anal pap smear, and HRA (if available) due to many possible false negatives when only an anal pap smear is done.¹⁰

TW with gender reconstructive surgery may consider testing through neovaginal pap smear(s) by a health care provider (HCP) to look for HPV-related cellular changes, although data on the effectiveness and resource implications of routine screening in this population is lacking.¹⁸

Speak to your HCP about anal screening using the information from the recent International Anal Neoplasia Society (IANS) guidelines (listed below); you may be referred to another provider for anal cancer screening. If you are not routinely seen by an HCP, such as a primary care physician (family doctor), check out the following service provider directory at **Rainbow Health Ontario**.²⁰

RISK FACTORS FOR ANAL CANCER

The risk factors for developing anal cancer include being part of the MSM community or TW community, living with HIV, smoking cigarettes, intravenous substance use and aging. Additionally, in PLHIV, having an AIDS diagnosis and/or having other STI infections may increase the risk.^{2,3,21,22} Due to an increased risk of anal cancer in PLHIV, it is important to adhere to antiretroviral therapy to maintain a robust immune system.^{5,21,23}

Talk to your partner(s)—current and within the past six months—about any warts, precancer and/or cancer you know about so they can get checked by their HCPs.^{2,10} Your HCP can also help notify your partners.²⁴

SCREENING GUIDELINES FOR ANAL CANCER

The Anal Cancer HSIL Outcomes Research (ANCHOR) study in 2021 was the largest work in anal cancer research in PLHIV. In this phase 3 trial, 4,446 participants aged 35 years and older with a biopsy-proven anal high-risk precancer helped develop the guidelines for anal cancer screening in cisgender and transgender PLHIV.^{11,25-27}

Results from the ANCHOR study concluded that anal cancer is the fourth most common cancer in PLHIV. As well, PLHIV have more types of HPV, and as they age while living with the virus(es), their corresponding risk for cancer increases. The rise in cancer probability is also due to a weaker immune system, which makes it easier for HPV to be become active in the body. The ANCHOR recommends that all PLHIV receive a DARE every year.^{11,28}

In 2024, the IANS developed the guidelines for groups at risk for anal cancer.⁷ The Centers for Disease Control—CDC—and National Institutes of Health—NIH—announced the new cancer prevention guidelines shortly, based in part on the information presented in the ANCHOR study. The chart below describes priority screening populations based on risk categories, minimum age recommendations to begin screening and methods for anal cancer screening.^{7,28} Figure 1. Population to screen for anal cancer. People living with HIV and people not living with HIV

| RISK CATEGORY A: PEOPLE LIVING WITH HIV | WHEN TO SCREEN | METHOD OF SCREENING | |
|--|---------------------------------|---|-------------------------------------|
| MSM living with HIV | Age 35 | Digital rectal examination + Anal cytology and/or anal HPV testing | |
| TW living with HIV | Age 35 | | |
| MSM and TW not living with HIV | Age 45 | | |
| Men living with HIV (not MSM) | Age 45 | | |
| Women living with HIV | Age 45 | | |
| History of vulvar dysplasia or vulvar cancer (in cisgender women and some TM) | Within one year of diagnosis | | |
| Solid organ transplant recipient | Ten years post-transplant | | |
| RISK CATEGORY B: SHARED DECISION MAKING WITH A HISTORY OF | | Abnormal results | Normal results |
| Perianal warts for male and female | Age 45 | High Resolution Anoscopy | Repeat screening in 1-2 years |
| Cervical/vaginal cancer | Age 45 | | |
| Cervical/vaginal HSIL* | Age 45 | | |
| Persistent HPV 16+ | Age 45 | | |
| Other immunosuppression or on chronic steroid therapy | Age 45 | | |

MSM, men who have sex with men; HIV, human immunodeficiency virus; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesions; TM, transgender men; TW, transgender women

*HSIL can develop into cancer

Figure adapted from https://onlinelibrary.wiley.com/doi/10.1002/ijc.34850.

TREATMENT FOR HPV, WARTS AND ANAL CANCER

There is no treatment to clear HPV. Instead, the effects of HPV infection are treated on a case-by-case basis.^{10,13}

A few options exist to treat HPV-related warts, including on-site medicines, freezing therapy and surgery. All treatments are done by HCPs, and most are completed over the course of several appointments. However, while anal warts may be removed from these methods, they may come back and require additional therapy sessions.²

Likewise with anal wart treatment, local medications, freezing and surgical options exist to combat anal precancer, as well as laser and laser and electrocautery (burning) therapies.^{10,29-31} Treating cells at this precancerous stage may cut the progression to anal cancer by over 50%.⁶

When someone has anal cancer, a combination of surgery, chemotherapy and radiation therapy may be used.^{8,9} The goals of these tools can range from taking out the cancer altogether to slowing down or limiting its spread in the body.⁹ Factors which guide HCPs on how to treat include the following: how far the cancer has advanced in the body, whether the person is living with HIV, if any cancer has remained after one round of treatment and if it has returned from a previously successful round of therapy.^{10,16}

In the ANCHOR study, it was found that there was a 57% reduction in anal cancer occurrence when people were treated during the anal precancer stage compared to those who were not. Early diagnosis and treatment may prevent anal cancer.¹¹

HPV INFECTION PREVENTION, VACCINE AND ANAL CANCER

Since HPV is usually acquired through sexual contact, consistent and correct barrier use (e.g., condoms and dental dams; use new ones with each new partner) during sex, male circumcision (foreskin removal; helpful for lowering chances of penile HPV infection) and having fewer sexual partners may lower your chances of getting HPV.^{1,3,10,32-37}

Condoms can include external ones for penises and sex toys, and internal ones for putting inside the anus and/or front hole.^{10,32-35} More information on how to use <u>internal</u>³² and <u>external</u>³⁴ condoms is available at <u>Planned Parenthood</u>.^{32,34}

The use of dental dams is controversial but may lower the chances of getting HPV through oral sex (including rimming), though less effectively than it may protect against other infections such as chlamydia or HIV.^{10,34,36} More information on how to use dental dams can be found at <u>Cleveland Clinic</u>.³⁶

Gardasil® 9 (HPV9) vaccine is recommended for individuals from 9 to 45 years of age, with greater cancer prevention potential in 9- to 26-year olds.^{1,37} The HPV vaccine protects against infection from the nine most common types of HPV which cause 80% to 90% of all cases: the two low-risk HPV types that cause most genital warts, and the seven high-risk HPV types that cause most HPV-related cancers.^{1,37} In people aged 15 years and older, the HPV9 vaccine is given in three doses over six months.³⁷ The vaccine is recommended and free of charge in Ontario for grade 7 students (regardless of gender identity or sex), as well as MSM and transgender individuals who have sex with men and are 26 years of age or younger, though it is available to others as well for about \$215 per dose.³⁷ Even if you already have one or more types of HPV, the vaccine may be useful to protect against others.¹⁰ Talk to your doctor to find out if HPV vaccination might benefit you.³⁷

Older adults may benefit less from the vaccine because they are more likely to have been exposed to HPV already. Therefore, vaccination is not routinely recommended for people in this age group.³⁸

In addition to sexual health choices, a diet rich in whole fruits, dark green vegetables and beans may have a protective effect against getting the high-risk type of HPV.³⁹

SEX, HPV AND STIGMA

Discussing sexual health can be difficult for many people. Open conversations with your HCP about sexual practices, including anal and oral sex, can help address HPV risks and prevent further complications.^{13,40}

Talk to your HCP about butt health including the new guidelines for people at risk of anal cancer, and if you can schedule an appointment for DARE and anal pap smear and/or HRA. If you are between 9 and 45 years of age, speak to your HCP about the HPV9 vaccine as well.³⁷

For more information on tips for discussion with your HCP check out the <u>Finding and Building a Therapeutic</u> <u>Relationship with your Healthcare</u> <u>Provider(s)</u>.⁴¹

SEX POSITIVE CARE

Sexual health practices should be considered alongside sexual pleasure. When discussing their sexual practices and sexual health, MSM and TW should feel empowered by their HCPs to take control of their sexual wellbeing.⁹

For example, HPV, warts and anal cancer—and their respective treatments may restrict how you have sex, either temporarily or permanently. However, by talking about changes in your body with your HCP, healthy alternatives can be explored that may still allow for a satisfying sex life. Every situation is unique, speak to your HCP about HPV and anal cancer screening.⁹

More helpful sex positive messaging can be found at the GMSH campaign <u>The Sex</u> <u>You Want</u>.⁴²

CANADIAN RESEARCH ON ANAL CANCER SCREENING AND HPV

In Ontario, a 3-year research study, Anal Cancer Equity in Screening Services Study (ACCESS) is in the initial stages of developing modules for clinicians on the implementation of equitable anal screening practices as recommended in new clinical guideline. The second research study is **The PEACH Study**, "CTN 330: Predicting and evaluating anal cancer in HIV with novel biomarkers." For more information, contact the principal investigator, **Dr. Grennan**.^{43,44}

REFERENCES

- HPV and cancer [Internet]. National Cancer Institute; 2023 Oct 18 [cited 2024 Aug 9]. Available from: <u>https://www.cancer.gov/</u> <u>about-cancer/causes-prevention/risk/</u> <u>infectious-agents/hpv-and-cancer</u>
- Pennycook KB, McCready, TA. Condyloma acuminata [Internet]. National Library of Medicine; 2023 Jun 21 [cited 2024 Aug 10]. Available from: <u>https://www.ncbi.nlm.nih.</u> gov/books/NBK547667/
- Medford RJ, Salit IE. Anal cancer and intraepithelial neoplasia: epidemiology, screening and prevention of a sexually transmitted disease. CMAJ. 2015 Feb 3;187(2):111-5. doi:10.1503/cmaj.140476
- 4. McIntosh RD, Andrus EC, Walline HM, Sandler CB, Goudsmit CM, Moravek MB, Stroumsa D, Kattari SK, Brouwer AF. Prevalence and Determinants of Cervicovaginal, Oral, and Anal Human Papillomavirus Infection in a Population of Transgender and Gender Diverse People Assigned Female at Birth. LGBT Health; 2024 Mar 25; doi: 10.1089/lgbt.2023.0335
- 5. As a trans man or non-binary person assigned female at birth, do I need to get screened for cervical cancer? Canadian Cancer Society; 2024 [cited 2024 Aug 28]. Available from: <u>https://cancer.ca/en/cancer-information/</u> <u>find-cancer-early/screening-in-lgbtq-</u> <u>communities/trans-man-or-nonbinary-</u> <u>person-assigned-female-at-birth-do-i-need-</u> <u>cervical-cancer-screening</u>
- 6. Thitipatarakorn S, Teeratakulpisarn N, Nonenoy S, Klinsukontakul A, Suriwong S, Makphol J, Hongchookiat P, Chaya-ananchot T, Chinlaertworasiri N, Mingkwanrungruang P, Sacdalan C, Poltavee K, Pankam T, Kerr SJ, Ramautarsing R, Colby D, Phanuphak N. Prevalence and incidence of anal highgrade squamous intraepithelial lesions in a cohort of cisgender men and transgender women who have sex with men diagnosed and treated during acute HIV acquisition in Bangkok, Thailand. J Int AIDS Soc. 2024 May 02;27(5):e26242. doi: 10.1002/jia2.26242

- Stier EA, Clarke MA, Deshmukh AA, Wentzensen N, Liu Y, Poynten IM, Cavallari EN, Fink V, Barroso LF, Clifford GM, Cuming T, Goldstone SE, Hillman RJ, Rosa-Cunha I, La Rosa L, Palefsky JM, Plotzker R, Roberts JM, Jay N. International Anal Neoplasia Society's consensus guidelines for anal cancer screening. Int J Cancer. 2024 Jan 31;154(10);1694-702. doi: 10.1002/ijc.34850
- Nicolau IA, Moineddin R, Antoniou T, Brooks JD, Gillis JL, Kendall CE, Cooper C, Cotterchio M, Salters K, Smieja M, Kroch AE, Lindsay JD, Price C, Mohamed A, Burchell AN. Trends in infection-related and infection-unrelated cancer incidence among people with and without HIV infection in Ontario, Canada, 1996-2020: a population-based matched cohort study using health administrative data. CMAJ Open. 2023 Oct 10;11(5):E894-905. doi: 10.9778/cmajo.20220230
- Dickstein DR, Edwards CR, Rowan CR, Avanessian B, Chubak BM, Wheldon CW, Simoes PK, Buckstein MH, Keefer LA, Safer JD, Sigel K, Goodman KA, Rosser BRS, Goldstone SE, Wong SY, Marshall DC. Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus. Nat Rev Gastroenterol Hepatol. 2024 Jun;21(6):377-405. doi:10.1038/s41575-024-00932-1
- Miller D. HPV, anal dysplasia and anal cancer [Internet]. Canadian AIDS Treatment Information Exchange; 2023 [cited 2024 Aug 13]. Available from: <u>https://www.catie.ca/ hpv-anal-dysplasia-and-anal-cancer</u>
- Palefsky JM, Lee JY, Jay N, Goldstone SE, Darragh TM, Dunlevy HA, Rosa-Cunha I, Arons A, Pugliese JC, Vena D, Sparano JA, Wilkin TJ, Bucher G, Stier EA, Tirado Gomez M, Flowers L, Barroso LF, Mitsuyasu RT, Lensing SY, Logan J, Aboulafia DM, Schouten JT, de la Ossa J, Levine R, Korman JD, Hagensee M, Atkinson TM, Einstein MH, Cracchiolo BM, Wiley D, Ellsworth GB, Brickman C, Berry-Lawhorn JM; ANCHOR Investigators Group. Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. N Engl J Med. 2022 Jun 16;386(24):2273-82. doi: 10.1056/ NEJMoa2201048

- 12. Non-sexually acquired human papillomavirus infection [Internet]. DermNet; 2024 [cited 2024 Aug 27]. Available from: <u>https://dermnetnz.org/topics/non-sexually-acquired-human-papillomavirus-infection#:~:text=Non%2Dsexually%20acquired%20HPV%20with,caregiver%20during%20a%20nappy%20change</u>
- 13. Human papillomavirus (HPV) and men: questions and answers [Internet]. Public Health Agency of Canada; 2024 Aug 07 [cited 2024 Aug 12]. Available from: <u>https:// www.canada.ca/en/public-health/services/ infectious-diseases/sexual-health-sexuallytransmitted-infections/hpv-men-questionsanswers.html</u>
- 14. Dysplasia [Internet]. National Cancer Institute; [cited 2024 Aug 7]. Available from: <u>https://www.cancer.gov/publications/dictionaries/cancer-terms/def/dysplasia</u>
- 15. Wei F, Gaisa MM, D'Souza G, Xia N, Giuliano AR, Hawes SE, Gao L, Cheng SH, Donà MG, Goldstone SE, Schim van der Loeff MF, Neukam K, Meites E, Poynten IM, Dai J, Combes JD, Wieland U, Burgos J, Wilkin TJ, Hernandez AL, Iribarren Díaz M, Hidalgo-Tenorio C, Valencia Arredondo M, Nyitray AG, Wentzensen N, Chow EP, Smelov V, Nowak RG, Phanuphak N, Woo YL, Choi Y, Hu Y, Schofield AM, Woestenberg PJ, Chikandiwa AT, Hickey AC, de Pokomandy A, Murenzi G, Péré H, Del Pino M, Ortiz AP, Charnot-Katsikas A, Liu X, Chariyalertsak S, Strong C, Ong JJ, Yunihastuti E, Etienney I, Ferré VM, Zou H, Segondy M, Chinyowa S, Alberts CJ, Clifford GM. Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. Lancet HIV. 2021 Sep;8(9):e531-43. doi: 10.1016/S2352-3018(21)00108-9
- Anal cancer treatment (PDQ[®])-patient version [Internet]. National Cancer Institute; 2024 Aug 7 [cited 2024 Aug 15]. Available from: <u>https:// www.cancer.gov/types/anal/patient/analtreatment-pdq# 26</u>
- **17.** Diagnosis of anal cancer [Internet]. Canadian Cancer Society; 2024 [cited Aug 18]. Available from: <u>https://cancer.ca/en/cancerinformation/cancer-types/anal/diagnosis</u>
- Fierz R, Ghisu GP, Fink D. Squamous Carcinoma of the Neovagina after Maleto-Female Reconstruction Surgery: A Case Report and Review of the Literature. Case Rep Obstet Gynecol. 2019 Jan 16;2019:4820396. doi: 10.1155/2019/4820396

- 19. Anoscopy and high-resolution anoscopy [Internet]. Johns Hopkins Medicine; 2024 [cited 2024 Aug 29]. Available from: <u>https://www.hopkinsmedicine.org/health/</u> <u>treatment-tests-and-therapies/anoscopyhigh-resolution-anoscopy</u>
- 20. Service provider directory [Internet]. Rainbow Health Ontario; 2024 [cited 2024 Aug 17]. Available from: <u>https://www. rainbowhealthontario.ca/lgbt2sq-health/</u> service-provider-directory/
- Anal cancer prevention (PDQ[®])-patient version [Internet]. National Cancer Institute; 2024 Apr 2 [cited 2024 Aug 17]. Available from: <u>https://www.cancer.gov/types/anal/</u> <u>patient/anal-prevention-pdq</u>
- 22. Waters AV, Dorsey KA, Allston A, Woods A, Furness BW, Doshi RK. Risk Factors for Human Papillomavirus-Associated Cancers Among People Living with HIV in Washington, District of Columbia. AIDS Res Hum Retroviruses. 2023 Apr;39(4):195-203. doi: 10.1089/AID.2022.0128
- 23. Almanzar A, Fazendin EA, Crean AJ, Stein DE. Anal cancer: the fundamentals [Internet]. Medscape; 2024 May 7 [cited 2024 Aug 27]. Available from: <u>https:// reference.medscape.com/slideshow/</u> <u>anal-cancer-6013824? gl=1*z5ee5b*_gcl</u> <u>au*MzAzMTQ3NDQuMTcyMjQ0MjM3MA..#1</u>
- Choi A, Campbell A, Consolacion T, Pawa J, Ng B, Wong J. Partner notification by family physicians for sexually transmitted infections: facilitators and barriers. Can Fam Physician. 2022 Jun;68(6):e182-9. doi: 10.46747/ cfp.6806e182
- 25. Treating anal cancer precursor lesions reduces cancer risk for people with HIV [Internet]. University of California San Francisco; 2021 Oct 7 [cited 2024 Aug 28]. Available from: <u>https://anchorstudy.org/ sites/default/files/newsletters/anchor press_release_07oct2021.pdf</u>
- 26. Stier EA, Clarke MA, Deshmukh AA, Wentzensen N, Liu Y, Poynten IM, Cavallari EN, Fink V, Barroso LF, Clifford GM, Cuming T, Goldstone SE, Hillman RJ, Rosa-Cunha I, La Rosa L, Palefsky JM, Plotzker R, Roberts JM, Jay N. International Anal Neoplasia Society's consensus guidelines for anal cancer screening. Int J Cancer. 2024 May 15;154(10):1694-702. doi: 10.1002/ijc.34850

- 27. ANCHOR study showed that treatment can prevent anal cancer [Internet]. theANCHORstudy.org; 2024 [cited 2024 Aug 28]. Available from: <u>https://anchorstudy.org/</u>
- 28. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV [Internet]. Clinical Info HIV.gov; 2024 Jul 9 [cited 2024 Aug 29]. Available from: <u>https://clinicalinfo.hiv.gov/en/ guidelines/hiv-clinical-guidelines-adult-andadolescent-opportunistic-infections/human</u>
- Treatment with hyfrecation and cryotherapy [Internet]. Anal Neoplasia Clinic, Research and Education Center; 2024 [cited 2024 Aug 8]. Available from: <u>https://ancre.ucsf.edu/</u> <u>treatment-hyfrecation-and-cryotherapy</u>
- Treatment with topical therapies [Internet]. Anal Neoplasia Clinic, Research and Education Center; 2024 [cited 2024 Aug 8]. Available from: <u>https://ancre.ucsf.edu/treatment-topical-therapies</u>
- **31.** Treatment with outpatient surgery [Internet]. Anal Neoplasia Clinic, Research and Education Center; 2024 [cited 2024 Aug 8]. Available from: <u>https://ancre.ucsf.edu/treatmentoutpatient-surgery</u>
- 32. Internal condom [Internet]. Planned Parenthood; 2024 [cited 2024 Aug 16]. Available from: <u>https://www. plannedparenthood.org/learn/birth-control/ internal-condom</u>
- 33. How do I use an internal condom [Internet]. Planned Parenthood; 2024 [cited 2024 Aug 16]. Available from: <u>https://www. plannedparenthood.org/learn/birth-control/ internal-condom/how-do-i-use-an-internalcondom</u>
- 34. How can I make sure I don't get or spread HPV [Internet]. Planned Parenthood; 2024 [cited 2024 Aug 16]. Available from: <u>https:// www.plannedparenthood.org/learn/stdshiv-safer-sex/hpv/how-can-i-make-sure-idont-get-or-spread-hpv</u>
- **35.** How to put a condom on [Internet]. Planned Parenthood; 2024 [cited 2024 Aug 16]. Available from: <u>https://www.</u> <u>plannedparenthood.org/learn/birth-control/</u> <u>condom/how-to-put-a-condom-on</u>
- 36. Dental dam [Internet]. Cleveland Clinic; 2022 May 3 [cited 2024 Aug 16]. Available from: <u>https://my.clevelandclinic.org/health/</u> <u>drugs/22887-dental-dam</u>

- 37. Human papillomavirus (HPV) vaccine fact sheet [Internet]. City of Toronto; 2024 Apr [cited 2024 Aug 10]. Available from: <u>https://www.toronto. ca/community-people/health-wellness-care/ diseases-medications-vaccines/humanpapillomavirus-hpv-vaccine/</u>
- 38. Human papillomavirus (HPV) viruses [Internet]. National Cancer Institute; 2021 May 25 [cited 2024 Aug 27]. Available from: <u>https://www.cancer.gov/about-cancer/ causes-prevention/risk/infectious-agents/ hpv-vaccine-fact-sheet</u>
- 39. Lin HY, Fu Q, Tseng TS, Zhu X, Reiss K, Joseph Su L, Hagensee ME. Impact of dietary quality on genital oncogenic Human Papillomavirus infection in women. J Infect Dis. 2023 Nov 11;228(10):1385-93. doi: 10.1093/infdis/jiad146
- 40. Kutner BA, Simoni JM, Aunon FM, Creegan E, Balán IC. How Stigma Toward Anal Sexuality Promotes Concealment and Impedes Health-Seeking Behavior in the U.S. Among Cisgender Men Who Have Sex with Men. Arch Sex Behav. 2021 May;50(4):1651-63. doi: 10.1007/s10508-019-01595-9
- **41.** Finding and building a therapeutic relationship with your healthcare provider(s) [Internet]. Gay Men's Sexual Health Alliance; 2022 Jun 30 [cited 2024 Aug 10]. Available from: <u>https://gmsh.ca/wp-content/</u> <u>uploads/2022/09/GMSH-Finding-A-</u> <u>HCP-E-2022.pdf</u>
- **42.** The sex you want [Internet]. Gay Men's Sexual Health Alliance; 2024 [cited 2024 Aug 8]. Available from: <u>https://thesexyouwant.ca/</u>
- 43. CTN 330: Predicting and evaluating anal cancer in HIV with novel biomarkers (The PEACH Study) [Internet]. CIHR Pan-Canadian Network for HIV and STBBI Clinical Trials Research; 2024 [cited 2024 Aug 27]. Available from: <u>https:// www.hivnet.ubc.ca/study/ctn-330-predictingand-evaluating-anal-cancer-in-hiv-with-novelbiomarkers-the-peach-study/</u>
- 44. Dr. Troy Grennan [Internet]. CIHR Pan-Canadian Network for HIV and STBBI Clinical Trials Research; 2024 [cited 2024 Aug 27]. Available from: <u>https://www.hivnet.ubc.ca/ our-investigators/dr-troy-grennan/</u>

GMSH.CA